507 related articles for article (PubMed ID: 21106276)
1. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
2. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
Xie H; Zeng L; Zeng S; Lu X; Zhang G; Zhao X; Cheng N; Tu Z; Li Z; Xu H; Yang L; Zhang X; Huang M; Zhao J; Hu W
Eur J Med Chem; 2012 Jun; 52():205-12. PubMed ID: 22475866
[TBL] [Abstract][Full Text] [Related]
3. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
7. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes.
Shan Z; Peng M; Fan H; Lu Q; Lu P; Zhao C; Chen Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1731-5. PubMed ID: 21334204
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of thiouracil derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Singh D; Gupta M
Chem Biol Drug Des; 2013 Feb; 81(2):257-64. PubMed ID: 23039850
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
11. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.
Zeng S; Xie H; Zeng LL; Lu X; Zhao X; Zhang GC; Tu ZC; Xu HJ; Yang L; Zhang XQ; Hu W
Bioorg Med Chem; 2013 Apr; 21(7):1749-55. PubMed ID: 23434133
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.
Nishio Y; Kimura H; Tosaki S; Sugaru E; Sakai M; Horiguchi M; Masui Y; Ono M; Nakagawa T; Nakahira H
Bioorg Med Chem Lett; 2010 Dec; 20(24):7246-9. PubMed ID: 21074430
[TBL] [Abstract][Full Text] [Related]
14. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.
Kato N; Oka M; Murase T; Yoshida M; Sakairi M; Yamashita S; Yasuda Y; Yoshikawa A; Hayashi Y; Makino M; Takeda M; Mirensha Y; Kakigami T
Bioorg Med Chem; 2011 Dec; 19(23):7221-7. PubMed ID: 22019046
[TBL] [Abstract][Full Text] [Related]
15. 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.
Nishio Y; Kimura H; Sawada N; Sugaru E; Horiguchi M; Ono M; Furuta Y; Sakai M; Masui Y; Otani M; Hashizuka T; Honda Y; Deguchi J; Nakagawa T; Nakahira H
Bioorg Med Chem; 2011 Sep; 19(18):5490-9. PubMed ID: 21865048
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
[TBL] [Abstract][Full Text] [Related]
17. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
18. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
Xie H; Zeng L; Zeng S; Lu X; Zhao X; Zhang G; Tu Z; Xu H; Yang L; Zhang X; Wang S; Hu W
Eur J Med Chem; 2013 Oct; 68():312-20. PubMed ID: 23994324
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Furuta Y; Sakai M; Horiguchi M; Masui Y; Okazaki K; Sato Y; Nakahira H
Bioorg Med Chem; 2012 Oct; 20(19):5864-83. PubMed ID: 22938786
[TBL] [Abstract][Full Text] [Related]
20. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
